XML 14 R23.htm IDEA: XBRL DOCUMENT
v3.20.1

Revenues (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2020
Revenue from Contract with Customer [Abstract] |
Disaggregation of revenue by product and by geographic area | Revenues were as follows (in millions):
|  | Three months ended March 31,
|  | 2020 |  | 2019
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
Enbrel® (etanercept) |  | $ | 1,117 |  |  | $ | 36 |  |  | $ | 1,153 |  |  | $ | 1,106 |  |  | $ | 45 |  |  | $ | 1,151 |
Prolia® (denosumab) |  | 422 |  |  | 232 |  |  | 654 |  |  | 390 |  |  | 202 |  |  | 592 |
Neulasta® (pegfilgrastim) |  | 534 |  |  | 75 |  |  | 609 |  |  | 893 |  |  | 128 |  |  | 1,021 |
XGEVA® (denosumab) |  | 355 |  |  | 126 |  |  | 481 |  |  | 356 |  |  | 115 |  |  | 471 |
Otezla® (apremilast) |  | 377 |  |  | 102 |  |  | 479 |  |  | — |  |  | — |  |  | — |
Aranesp® (darbepoetin alfa) |  | 175 |  |  | 247 |  |  | 422 |  |  | 182 |  |  | 232 |  |  | 414 |
KYPROLIS® (carfilzomib) |  | 187 |  |  | 93 |  |  | 280 |  |  | 154 |  |  | 91 |  |  | 245 |
Repatha® (evolocumab) |  | 124 |  |  | 105 |  |  | 229 |  |  | 83 |  |  | 58 |  |  | 141 |
Other products |  | 988 |  |  | 599 |  |  | 1,587 |  |  | 827 |  |  | 424 |  |  | 1,251 |
Total product sales(1) |  | $ | 4,279 |  |  | $ | 1,615 |  |  | 5,894 |  |  | $ | 3,991 |  |  | $ | 1,295 |  |  | 5,286 |
Other revenues |  |  |  |  |  | 267 |  |  |  |  |  |  | 271 |
Total revenues |  |  |  |  |  | $ | 6,161 |  |  |  |  |  |  | $ | 5,557 |
____________ (1) Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2020 and 2019.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration